



## Personalized medicine, improves response rate to cisplatin in patients with non-small cell lung cancer


### Technology

The miRNA research field is of interest for the future and is now well established that miRNAs represent new potential therapeutic targets as well as relevant diagnostic / prognostic biomarkers.

Nearly 60% of patients with non-small cell lung cancer are resistant to cisplatin, a first-line anti-cancer agent.

The research teams in this project have identified a specific miRNA as a genetic factor involved in these resistances.

miR-X is both a biomarker that can predict resistance to chemotherapy and a new therapeutic target allowing combined treatment against lung cancer.



### Benefits

- **Diagnosis:** Predictive biomarker of response for patients treated with cisplatin allowing a dedicated treatment. Biomarker monitoring the effectiveness of this same treatment.
- **Therapeutic:** Improved response rate to cisplatin in patients with non-small cell lung cancer.

### Applications

- Personalized medicine
- Non-small cell lung cancer

### Keywords

- NSCLC
- miRNA
- LNA-oligonucleotide
- Personalized medicine
- Biomarker

### Intellectual Property

EP 16306563.4  
priority date : 25th of november 2016

### Development Status

**Therapeutic:**  
POC in vitro & in vivo upcoming

**Diagnosis:**  
Validation of the predictive biomarker upcoming

### Partnership

Out-licensing or Partnerships

contact

**Anthony DACCACHE, Ph.D.**

Business Developer

+33 6 13 84 39 39

anthony,daccache@sattnord.fr

find other technologies on

[www.sattnord.fr](http://www.sattnord.fr)

SATT Nord

25, avenue Charles St Venant – 59800 LILLE – France

+33 3 28 36 04 68 – [tech@sattnord.fr](mailto:tech@sattnord.fr)

